Beta Bionics, Inc. Common Stock (BBNX) - Total Liabilities
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has total liabilities worth $39.59 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Beta Bionics, Inc. Common Stock to assess how effectively this company generates cash.
Beta Bionics, Inc. Common Stock - Total Liabilities Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Check BBNX asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Beta Bionics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Datang Corporation Renewable Power Co. Limited
F:DT7
|
Germany | €77.62 Billion |
|
Dalian Zhiyun Automation Co Ltd
SHE:300097
|
China | CN¥420.80 Million |
|
Beijing Transtrue Technology Inc
SHE:002771
|
China | CN¥289.55 Million |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩295.72 Billion |
|
Binh Minh Plastics JSC
VN:BMP
|
Vietnam | ₫501.38 Billion |
|
Hota Industrial Mfg. Co Ltd
TW:1536
|
Taiwan | NT$13.59 Billion |
|
Calavo Growers Inc
NASDAQ:CVGW
|
USA | $83.69 Million |
Liability Composition Analysis (2022–2025)
This chart breaks down Beta Bionics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Beta Bionics, Inc. Common Stock worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beta Bionics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual total liabilities of Beta Bionics, Inc. Common Stock from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $39.59 Million | -46.24% |
| 2024-12-31 | $73.63 Million | +43.16% |
| 2023-12-31 | $51.43 Million | +128.31% |
| 2022-12-31 | $22.53 Million | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch P… Read more